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Frequency of carried vaccine serotypes decreased significantly across lineages post-
PCV13 introduction in Malawi. There is an increase of serotypes 7C, 15B/C, 23A and 
28F post-PCV13 introduction. Antibiotic resistance rates remained stable but certain 
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Background. Pneumococcal conjugate vaccines (PCV) have reduced pneumococcal 
diseases globally. Pneumococcal genomic surveys elucidate PCV effects on population 
structure but are rarely conducted in low-income settings despite the high disease 
burden. 
 
Methods. We undertook whole genome sequencing of 660 pneumococcal isolates 
collected through surveys from healthy carriers two years from PCV14 introduction and 
one-year post-rollout in northern Malawi. We investigated changes in population 
structure, within-lineage serotype dynamics, serotype diversity, and frequency of antibiotic 
resistance (ABR) and accessory genes. 
 
Results. In the under-fives, frequency and diversity of vaccine serotypes (VT) decreased 
significantly post-PCV but no significant changes occurred in over-fives. Clearance of VT 
serotypes was consistent across different genetic backgrounds (lineages). There was an 
increase of non-vaccine serotypes (NVT) namely 7C, 15B/C, 23A in under-fives but 28F 
increased in both age groups. While carriage rates have been recently shown to 
remain stable post-PCV due replacement serotypes, there was no change in diversity of 
NVTs. Additionally, frequency of intermediate-penicillin-resistant lineages decreased post-
PCV. While frequency of ABR genes remained stable, other accessory genes especially 
those associated with MGEs and bacteriocins showed changes in frequency post-PCV. 
 
Conclusions. We demonstrate evidence of significant population restructuring post-PCV 
driven by decreasing frequency of vaccine serotypes and increasing frequency of few 
NVTs mainly in under-fives. Continued surveillance with WGS remains crucial to fully 
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Pneumococcal conjugate vaccines (PCV) have demonstrated high effectiveness on non-
invasive [1] and invasive pneumococcal disease (IPD) [2]. Approximately 70% reduction 
of IPD was observed in USA post-PCV7 introduction with >90% reduction of vaccine 
serotypes (VTs) [2]. PCV7 was not widely introduced in Sub Saharan Africa (SSA) due 
to predicted low VT coverage against common serotypes including 1 and 5 [3]. South 
Africa was among few countries in SSA to implement PCV7 and >85% reduction in 
IPD which included HIV-infected individuals was reported [4]. Subsequent higher-valent 
PCVs (PCV10 and PCV13) have shown high effectiveness in SSA in on VT carriage 
(>65%) [5] and IPD (>80%) in SSA [6, 7] consistent with reports in high-income 
countries [8].  
 
While reduction of VT carriage has been documented post-PCV [9], the effect of PCV 
on overall carriage rates and density is not substantial [10, 11] because of serotype 
replacement post-PCV (increase of NVTs) [12, 13]. Such replacement is prompted by 
rewiring of strain competition dynamics when VTs become uncommon. The replacement 
NVTs can be novel (imported or capsule-switched) or extant due to clonal expansion of 
previously suppressed NVT serotypes. While replacement NVTs are less invasive than 
VTs, this is not universally true, and some strains retain propensity for IPD [14]. 
Therefore, post-PCV surveillance is crucial to monitor serotype frequency and 
interactions to inform optimal future PCV formulations. Pneumococcal surveillance 
typically focuses on IPD but monitoring of carriage is also crucial because that’s the 
niche where evolution occurs therefore influence population-level dynamics unlike IPD 
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PCV13 was introduced in Malawi on 12 November 2011 as an accelerated ‘3+0’ 
schedule at 6, 10 and 14 weeks with a limited catch-up for infants in the first year 
from introduction. For the catch-up campaign, infants aged <12 months at the date of 
vaccine introduction were eligible for the following 12 months to receive 3 doses of 
PCV13 but coverage for the three doses of PCV13 was lower in catch-up infants (~50-
70%)  than in birth-eligible children (~90-95%) [15]. Recent carriage studies have 
reported a reduction of VTs but no overall change in carriage rates [16]. In this study, 
we undertook whole genome sequencing (WGS) of pneumococcal isolates from northern 
Malawi to investigate early changes in population re-structuring, within-lineage serotype 
composition, serotype diversity, antibiotic resistance (ABR) and accessory genome 
dynamics pre- and post-PCV. The WGS was part of the Global Pneumococcal 
Sequencing (GPS) project (www.pneumogen.net), which has sequenced ~23,000 isolates 
globally to study pneumococcal evolution patterns post-PCV to inform future vaccine 
design. 
 
Materials and methods 
Study population and isolate selection 
Household surveys of healthy carriers were conducted in Karonga district of northern 
Malawi pre-PCV between 2009-2011 and post-PCV in 2014 and there was no 
significant changes of the overall pneumococcal carriage rates [16]. We randomly 
selected a subset of the samples (n=660) pre-PCV in 2009-2010 (n=482) and post-PCV 
in 2014 (n=178) for a WGS survey (Supplementary Data 1). The mean age for 
samples collected pre-PCV was 6.24 (95% CI: 5.30-7.17) and 4.84 (95% CI: 3.79-5.89) 
post-PCV. The age ranged from 3 days to 54 years old and one month to 30 years 
old pre-PCV and post-PCV respectively. In terms of age group, 506 samples collected 
pre-PCV were from under-fives (n=376, mean: 1.70 years old [95% CI: 1.53 to 1.86]) 
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collected post-PCV in under-fives (n=106, mean: 1.35 [95% CI: 1.05-1.65]) and over-
fives (n=48, mean: 14.29 [95% CI: 12.08-16.50]).  
 
The nasopharyngeal swabs were processed as previously described [16]. Informed 
written consent was obtained from adults, and parents, guardians and caregivers of 
child participants. The study was approved by National Health Sciences Research 
Committee in Malawi (#490 and #1232), London School of Hygiene and Tropical 
Medicine (#5345), University of Liverpool (#670) and University of Malawi College of 
Medicine Research Ethics Committee (#P.O8/14/1614). 
 
Genomic DNA sequencing and analysis 
Procedures for genomic DNA extraction and sequencing were described previously [17]. 
The sequence reads were assembled using an automated assembly pipeline [18]. The 
serotypes and sequence types (ST) were identified using seroBA [19] and multi-locus 
sequence typing [20] while ABR genes were detected using nucleotide-BLAST v2.2.30 
(E-value<0.001, sequence coverage and identity >80%) [21]. Penicillin minimum inhibitory 
concentrations (MIC) were genotypically predicted using the Centers for Disease Control 
and Prevention’s (CDC) pipeline [22] and the MICs were interpreted using the British 
Society for Antimicrobial Chemotherapy breakpoints [23]. The sequence reads were 
deposited in the European Nucleotide Archive under accession numbers in 
Supplementary Data 1. 
 
Genomic clusters (GC) or lineages were inferred using BAPS v6.0 [24]. A 1,050,021bp 
core-gene-alignment with 88,961 single nucleotide polymorphism (SNP) positions was 
generated using Roary [25]. Phylogenetic trees for all isolates was constructed using 






/cid/advance-article-abstract/doi/10.1093/cid/ciz404/5490137 by The U
niversity of Edinburgh user on 19 June 2019
 
 9 
consensus alignments from SMALT (https://sourceforge.net/projects/smalt/) for Gubbins 
v1.4.10 [27] and RAxML v7.0.4 [28]. The SNPs were reconstructed on the trees using 
parsimony. The trees were visualised using iToL v2.1 [29] and MicroReact [30]. 
 
Statistical analysis 
Serotype and ABR gene frequencies were compared using Fisher’s Exact test. The 
Simpson diversity index (D) for serotype and ST composition were estimated using a 
web-based analysis tool (www.comparingpartitions.info). The differences in penicillin MICs 
were assessed using Student’s t-test. The binary presence-absence of accessory genes 
pre- and post-PCV was assessed using logistic regression, which controlled for vaccine 
status and age group of the isolates with Bonferroni correction for multiple testing. We 
used R v3.1.2 for statistical analyses (R Core Team, 2013, www.r-project.org). 
 
Results 
Defining the population structure 
Whole genomes sequences for the 660 carried isolates revealed 45 serotypes and 169 
sequence types (STs) (Supplementary Data 1). The majority of the serotypes were 
associated with a single phylogenetic tree branch with few serotypes dispersed across 
multiple unrelated branches due to capsule-switching (acquisition of the capsule/serotype 
in unrelated strains). To account for genetic background of the isolates, we defined 23 
lineages or genomic clusters (GC) using unsupervised nucleotide sequence clustering 
and these lineages allowed for subsequent comparison of serotype changes in context 
of their lineage membership (Figure 1a). Phylogenetically, all the lineages (GC1-22) 
except for GC23 were monophyletic with their members emerging from a single recent 
common ancestor. The defined lineages varied in composition of serotypes and 
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higher diversity) or age (older lineages accrue more diversity). An interactive 
phylogenetic tree of the isolates is available in MicroReact 
(https://microreact.org/project/xH7-VcoWj/8a339d57). 
 
Frequency of vaccine serotypes and their associated lineages 
The frequency of lineages GC3 (P=0.002), GC16 (P=0.004) and GC17 (P=0.004) in 
under-fives increased post-PCV while lineages GC10 (P=0.016) and GC19 (P=0.026) 
showed a decrease in the same age group (Figure 2a, Supplementary Table 1). These 
were predominantly VT-associated lineages therefore their decreased frequency reflects 
reduction of VTs in isolates sampled from the under-fives, which comprised of the 
majority of vaccinated individuals, but this reduction was not seen in the unvaccinated 
over-fives population (Figure 2b, Supplementary Table 2). However, despite the 
observed decrease in frequency of VTs in lineages, the odds ratio for VT serotypes in 
each lineage in under-fives relative to over-fives remained unchanged post-PCV except 
for lineages GC4 and GC16 in which the odds ratio (OR) for VTs increased and 
lineages GC19 and GC21 where the OR decreased (Supplementary Table 3). By 
individual serotypes, frequency of multiple NVTs increased post-PCV namely serotypes 
7C (P=0.001), 15B/C (P=0.004), 23A (P=0.017) and 28F (P=0.0001) in under-fives and 
28F (P=0.029) in over-fives (Figure 2c and Supplementary Table 4). There overall 
frequency of VTs regardless of lineages decreased post-PCV in under-fives (60.08-
33.08%; P=4.80 10-8) but not over-fives (42.45-33.33%; P=0.3739) (Figure 2d and 
Supplementary Table 5). However, the frequency of VTs was higher in under-fives than 
over-fives (P=8.44 10-4) pre-PCV but no differences were observed post-PCV (Figure 2d, 
Supplementary Table 4,5). 
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Within-lineage dynamics revealed how serotype frequency were changing post-PCV. For 
example, clonal expansion of serotypes 11A (GC7) and 15B/C (GC16) occurred post-
PCV (Figure 3). By comparing pre- and post-PCV frequencies of serotypes in the 
lineages it was clear that the majority of the serotypes were extant pre-PCV while a 
few were first detected post-PCV in some lineages for example serotype 19F (GC13) 
and 19A (GC20), which were capsule-switch events. Comparison of overall serotype 
frequencies revealed that serotype 28F (GC2 and GC21) was the only serotype not 
detected pre-PCV, which posed questions regarding whether it emerged by recent 
importation or post-PCV unmasking after prior circulation pre-PCV at undetectable level. 
Genomic analysis showed that GC21 contained serotype 9V and the 28F amongst 9V 
strains in GC21 emerged post-PCV by a 9V 28F vaccine capsule-switch and the 
capsule-switched isolates were distinguished by ~20 SNPs within themselves and with 
closest 9V isolates. However, accrued genetic diversity of 28F isolates in GC2 was 
higher than expected to occur under pneumococcal mutation rate if the isolates 
emerged post-PCV (maximum 6,757 SNPs) (Figure 4). Because recently imported 
isolates typically undergoes a loss in genetic diversity (bottleneck), our findings were 
not consistent with this therefore implied that serotype 28F isolates existed at 
undetectable levels pre-PCV and were unmasked due to clearance of VTs post-PCV, 
which subsequently led to the serotype 9V 28F vaccine capsule-switch in GC21. There 
was further evidence against importation from other countries because serotype 28F 
with similar genetic profiles were uncommon globally (2/12000 in GPS collection) and 
these differed from our isolates by >2000 SNPs therefore could not be the source. 
Additional capsule-switched isolates detected post-PCV only included 11A 20 (GC7), 
13 19A (GC9), 16F 19F (GC13), (GC21), and 7C NT (GC23) but none of these 
were vaccine-escape events. 
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The pre-PCV equilibrium diversity of serotypes is altered by PCV therefore changes in this 
diversity in VTs and NVTs quantified using Simpson diversity index (D) can signal 
population-level PCV effectiveness. In this study, Simpson’s D for serotypes decreased 
post-PCV in VTs in under-fives (P=0.022) but not over-fives (Figure 4a, 6 Table). 
However, Simpson’s D appeared to decrease and increase in NVTs in under-fives and 
over-fives respectively although not significant statistically (Figure 5). The Simpson’s D 
for serotypes was similar between VTs and NVTs pre-PCV, but it was higher in NVTs 
than VTs post-PCV (P=0.004) (Figure 5b). The Simpson’s D was higher for STs than 
serotypes both pre-PCV (P=0.011) and post-PCV (P=0) but remain unchanged post-PCV 
therefore ST diversity may not be informative of PCV effect (Supplementary Table 6,7). 
 
Frequency of antibiotic resistance and other accessory genes 
An important subset of pneumococcal accessory genes encodes for ABR-conferring 
proteins therefore we assessed their distribution pre- and post-PCV. The genes confer 
resistance against tetracycline, chloramphenicol and erythromycin. No significant changes 
in frequency of ABR genes (rates) occurred post-PCV (Figure 6a-b, Supplementary 
Table 8). We also assessed MICs changes in penicillin resistance genotypically and 
similarly resistance rates were unchanged although the MICs decreased post-PCV 
(P=0.0098) due to clearance of intermediate-resistant VT isolates in GC12 (Figure 6c).  
 
To assess whether other accessory genes had changed in frequency post-PCV unlike 
ABR genes, logistic regression model was fitted to binary gene presence-absence data 
with sampling period of the isolates as independent variable adjusted for PCV status 
and age group. Significant changes in frequency were detected in forty-two accessory 
genes post-PCV after Bonferroni correction (Figure 7, Supplementary Table 9). There 
was an increasing trend in half of the genes with lowest P-values associated with 
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restriction modification system (OR=3.34, P=3.46 10-5). Conversely, bacteriocin gene blpQ 
(OR=0.19, P=5.20 10-6) showed the most significant decrease. The capsule biosynthesis 
gene wzx also decreased post-PCV (OR=0.43, P=0.042). By functional classification, 




Pneumococcal evolution occurs during carriage therefore monitoring carriage population 
is crucial to understand ongoing strain dynamics and adaptations post-PCV [4, 5]. Our 
genomic study demonstrates the utility of WGS in monitoring changes in pneumococcal 
carriage in low-income settings post-PCV introduction. We provide evidence of early 
pneumococcal population restructuring using WGS observed beyond serotype but also at 
lineage and accessory genome level in both children and adults two years post-PCV 
introduction. The most significant finding is that decrease of VTs occurred consistently 
across their associated lineages reflecting no interference of genetic background on 
PCV effectiveness, and most importantly the collective decrease of VTs was more 
pronounced in under-fives, which implies high direct PCV effects consistent with data 
from clinical trials [16]. However, our findings show modest decrease in frequency of 
VTs and VT-associated lineages in over-fives which implies either limited or delayed 
indirect PCV effects in contrast to other settings where higher indirect effects have 
been demonstrated in older population [9, 31]. It is currently unclear whether limited 
indirect PCV effects in our setting is related to PCV scheduling or mitigating factors for 
herd effects such as HIV-infected adults considered as potential reservoir for 
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PCV implementation changes both frequency of individual serotypes and their 
composition in the population therefore quantifying the degree of disorder of serotypes 
with Simpson diversity index can indirectly inform population-level PCV effects [33, 34]. 
Our findings showed that serotype diversity in VTs decreased significantly post-PCV but 
only in under-fives, which implies substantial loss of diversity in VTs in vaccinated 
under-fives but not older unvaccinated individuals consistent with the serotype-frequency-
based observation of high direct PCV effect but limited indirect effects. We expected 
an increase in serotype diversity in NVTs due to serotype replacement, on the 
contrary, this did not occur in both age groups, which implies that while the overall 
carriage rate was rapidly restored by replacement NVTs, these resulted in marginal 
accrual of additional diversity in NVTs post-PCV. This may be a consequence of 
incomplete serotype replacement process because the isolates were sampled only two-
years post-PCV introduction. However, increase in frequency of individual NVTs occurred 
for serotypes 7C, 23A and 15B/C in under-fives, and 28F in both age groups and 
these have been reported elsewhere except for serotype 28F [35, 36]. Unlike other 
serotypes, 28F was detected only post-PCV in lineages (GC2 and GC21), which initially 
prompted speculation that it was imported from another country. However, within-lineage 
genetic diversity of 28F isolates and genetic dissimilarity from similar isolates in the 
GPS collection ruled out importation because the genetic diversity was much higher 
than can be expected for a newly introducted clone, which suggested that it had been 
circulation pre-PCV but at undetectable levels. Interestingly, the serotype 28F in GC21 
emerged post-PCV via a vaccine-escape 9V 28F capsule switch between unmasked 
28F in GC2 and 9V isolates in GC21 but there were no other vaccine-escape capsule 
switches detected for other serotypes. Therefore, the rarity of vaccine-escape capsule-
switches demonstrates negligible effect of capsule-switching process on serotype 
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The pneumococcal accessory gene pool consists of a diverse repertoire of genes, 
which include ABR, MGE and competition-associated genes. We noted stability in 
frequency of ABR genes post-PCV but considering that the levels were already low 
unlike in IPD isolates in Malawi this did not raise concerns [37-39]. Interestingly, PCV 
reduced frequency of intermediate-penicillin-resistant isolates associated with VT-lineages, 
which showcases how PCV can be strategically harnessed as a preventative strategy to 
thwart emergence of high resistance by targeting low-level resistance lineages with 
highest likelihood to express full resistance in future [40]. Other non-ABR-associated 
accessory genes showed changes in frequency post-PCV after controlling for age group 
and vaccine status of the isolates and these predominantly included highly mobile and 
rapidly shared MGE-associated genes and bacteriocin immunity proteins, which mediates 
isolate competition therefore suggests potential benefits in emerging NVTs as 
pneumococcal population re-establishes equilibrium serotype dynamics. 
 
Our findings demonstrate early changes in the pneumococcal carriage population in a 
low-income setting post-PCV introduction. Our findings provide the first large-scale post-
PCV genomic survey of carried pneumococcal isolates in an African setting where 
despite high disease burden, limited WGS studies are conducted therefore this study 
provides useful baseline data for comparative analyses of population-level effects of 
PCV between different settings both low and high-income. The play of chance and 
possibly small sample sizes for subset analyses could have impacted some of our 
findings therefore cautious interpretation is recommended. Continued diligent surveillance 
and WGS remain crucial for monitoring long-term residual effects VTs, serotype 
replacement and genotypic changes post-PCV after equilibrium serotype dynamics are 
re-stablished. Additionally, our study complements vaccine efficacy data from clinical 
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SSA and globally, which will help to inform optimal combination of serotypes for future 
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Figure 1. Sampling location, genetic similarity and distribution of carried pneumococcal 
isolates. The map of Africa shows the location of Malawi and Karonga district where 
the isolates were sampled from. The number of isolates (n=660) used in the genomic 
analysis are shown in the table below the phylogenetic tree. The core genome 
maximum likelihood phylogenetic tree of the 660 carriage isolates rooted at the branch 
of ‘classical’ non-typeables (NT). The tips (circles) of the tree are coloured by serotype 
and coloured strips panels to the right correspond to serotype, genomic clusters (GC) 
or lineage, vaccine status, sampling period and age group. The tree with metadata and 
corresponding international definitions of the pneumococcal lineages is available 
interactively online at https://microreact.org/project/xH7-VcoWj/8a339d57. 
 
Figure 2. Frequency of lineages and serotypes in carriage. (a) Frequency of lineages 
pre- and post-PCV in under-fives and over-fives. (b) Frequency of VTs in lineages pre- 
and post-PCV in under-fives and over-fives. (c) Volcano plots showing odds ratio (OR) 
of individual serotypes pre- and post-PCV in under-fives and over-fives. The x-axis 
show magnitude (log2 [OR]) and y-axis show statistical significance (-log10 P-value). (d) 
Frequency of VTs in under-fives and over-fives. Statistically significant changes are 
marked as follows: ‘ns’: not significant, P<0·05 (*), P<0·01 (**) and P<0·001 (***). The 
comparative estimates of prevalence for serotypes, lineages and odds ratios are 
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Figure 3. Dynamics of pneumococcal lineages and serotypes. The leftward facing 
stacked bar graph shows frequency of lineages in under-fives while the rightward facing 
bar graph shows frequency of lineages and their constituent serotypes in over-fives pre- 
and post-PCV introduction. The bar graphs are aligned by genomic clusters (GC) for 
easy comparisons of frequency of serotypes pre- and post-PCV between the two age 
groups. The serotypes are distinguished by different colours in the bar graphs as 
described in the key. The GC23 is the ‘bin’ cluster because it consists of isolates not 
placed in monophyletic clusters GC1-22. The lineages whose frequency changed 
significantly post-PCV are marked as follows: P<0.05 (*) and P<0.01 (**) and those 
with borderline significance P<0.095 (.). The Fisher’s exact test was used to determine 
P-values. 
 
Figure 4. Genetic diversity of a recently emerged serotypes (28F). Boxplots showing 
within (Malawi) and between country (Malawi and South Africa) genetic diversity of 
serotype 28F isolates showing in (a) GC2 and (b) GC21. Lineage GC21 also include 
serotype 9V isolates, which some of which underwent a capsule-switch to acquire a 
serotype 28F capsule. 
 
Figure 4. Serotype composition and diversity in context of PCV. (a) Simpson diversity 
index for composition of serotypes between pre- and post-PCV datasets among VT, 
NVT and all isolates among isolates. (b) Simpson diversity index for composition of 
serotypes between VT and NVT isolates sampled pre- and post-PCV. Statistically 
significant changes are marked as follows: ‘ns’: not significant, P<0.05 (*), P<0.01 (**) 
and P<0.001 (***). The estimates and P-values for frequency of VTs and Simpson 
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Figure 5. Genetic diversity of a recently emerged serotypes (28F). Boxplots showing 
within (Malawi) and between country (Malawi and South Africa) genetic diversity of 
serotype 28F isolates showing in (a) GC2 and (b) GC21. Lineage GC21 also include 
serotype 9V isolates, which some of which underwent a capsule-switch to acquire a 
serotype 28F capsule. 
 
Figure 6. Distribution of antibiotic resistance genes and MGEs pre- and post-PCV. (a) 
Distribution of chloramphenicol resistance gene (catpC194), erythromycin resistance gene 
(mefA, mefE and ermB), tetracycline resistance gene (tetM) and penicillin resistance 
genes across the phylogenetic tree of the carried pneumococcal isolates. Presence and 
absence of genes is indicated by colored branches and innermost ring surrounding the 
phylogeny as shown in the key at the bottom of each tree. (b) Frequency of genotypic 
ABR rates for chloramphenicol, erythromycin, tetracycline and intermediate-penicillin-
resistance pre- and post-PCV. (c) Distribution of penicillin MICs pre- and post-PCV. The 
subsets with statistically significant changes are marked as follows: ‘ns’: not significant, 
P<0.05 (*), P<0.01 (**) and P<0.001 (***). The estimates for frequency of the ABR 
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Figure 7. Pneumococcal accessory genome dynamics. The distribution of 2,591 
intermediate-frequency-accessory genes in the entire pneumococcal population. The 
volcano plot shows magnitude (log2 OR) on the x-axis and statistical significance (-log10 
P-value) and odds ratio for presence of accessory genes post-PCV relative to pre-PCV 
after controlling for vaccine status and age group of the isolates. The points were 
coloured by adjusted P-values after correcting for multiple testing using Bonferroni 
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